COVID‐19 and coagulopathy. (30th August 2021)

• Record Type: Journal Article
• Authors: Sarkar, Malay; Madabhavi, Irappa V.; Quy, Pham Nguyen; Govindagoudar, Manjunath B.
• Is Part Of: Clinical respiratory journal. Volume 15:Number 12(2021)
• Page Start: 1259
• Page End: 1274
• Publication Date: 2021-08-30
• Subjects: COVID‐19 -- endotheliitis -- heparin -- microthrombosis -- thrombosis; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Periodicals; 616.24
• DOI: 10.1111/crj.13438
• Languages: English
• ISSNs: 1752-6981

Abstract

Abstract: The SARS‐CoV‐2 is a new coronavirus responsible for the COVID‐19 disease and has caused the pandemic worldwide. A large number of cases have overwhelmed the healthcare system worldwide. The COVID‐19 infection has been associated with a heightened risk of thromboembolic complications. Various mechanisms are leading to the high thrombotic risk in COVID‐19 patients such as inflammation, endotheliitis, hyperviscosity, and hypercoagulability. We searched PubMed, EMBASE, and CINAHL from January 2020 to December 2020. We used the following search terms: COVID‐19, coagulopathy, and thrombosis. We reviewed the epidemiology, clinical features, mechanisms, and treatment of COVID‐19‐associated coagulopathy.